This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05792/identifier/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05792/identifier/chemspider/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05792/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05792
rdf:type
n3:Drug
n3:description
SR31747 is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
n3:generalReferences
# Paul R, Silve S, De Nys N, Dupuy PH, Bouteiller CL, Rosenfeld J, Ferrara P, Le Fur G, Casellas P, Loison G: Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9618436 # Casellas P, Galiegue S, Bourrie B, Ferrini JB, Jbilo O, Vidal H: SR31747A: a peripheral sigma ligand with potent antitumor activities. Anticancer Drugs. 2004 Feb;15(2):113-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15075666
n3:group
investigational
n3:indication
Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer.
owl:sameAs
n8:DB05792
dcterms:title
SR 31747
adms:identifier
n6:6439330 n9:4943746 n10:DB05792
n3:mechanismOfAction
SR31747 blocks proliferation of human lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner.
n3:IUPAC-Name
n4:271B46A6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B46AC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B46AB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B46A8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B46A9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B46AA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B46A5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B46B2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B46B3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B46AD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B46AE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B46B0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B46AF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B46B1-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B46B7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B46B9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B46BA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B46B6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B46B5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B46B8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B46A7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B46B4-363D-11E5-9242-09173F13E4C5